The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Eosinophilic Granulomatosis Market Research Report 2025
Synopsis
Eosinophilic granulomatosis also known as Churg-Strauss syndrome is a rare autoimmune disorder characterized by multiple sign and symptoms such as acute asthma, inflammation, sinusitis, and nerve damage.
The global Eosinophilic Granulomatosis market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Eosinophilic Granulomatosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eosinophilic Granulomatosis.
Report Scope
The Eosinophilic Granulomatosis market size, estimations, and forecasts are provided in terms of sales volume (Kiloton) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Eosinophilic Granulomatosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eosinophilic Granulomatosis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Pharmaceuticals Holdings
Baxter
Genentech(Roche)
Cephalon(Teva)
Amgen
Sanofi
DSM
AstraZeneca
Novartis International
Segment by Type
Oral
Intravenous
Others
Segment by Application
Hospital Pharmacies
Drug Stores
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eosinophilic Granulomatosis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eosinophilic Granulomatosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Eosinophilic granulomatosis also known as Churg-Strauss syndrome is a rare autoimmune disorder characterized by multiple sign and symptoms such as acute asthma, inflammation, sinusitis, and nerve damage.
The global Eosinophilic Granulomatosis market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Eosinophilic Granulomatosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eosinophilic Granulomatosis.
Report Scope
The Eosinophilic Granulomatosis market size, estimations, and forecasts are provided in terms of sales volume (Kiloton) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Eosinophilic Granulomatosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eosinophilic Granulomatosis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Pharmaceuticals Holdings
Baxter
Genentech(Roche)
Cephalon(Teva)
Amgen
Sanofi
DSM
AstraZeneca
Novartis International
Segment by Type
Oral
Intravenous
Others
Segment by Application
Hospital Pharmacies
Drug Stores
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eosinophilic Granulomatosis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eosinophilic Granulomatosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Eosinophilic Granulomatosis Market Overview
1.1 Product Overview and Scope of Eosinophilic Granulomatosis
1.2 Eosinophilic Granulomatosis Segment by Type
1.2.1 Global Eosinophilic Granulomatosis Market Value Comparison by Type (2024-2030)
1.2.2 Oral
1.2.3 Intravenous
1.2.4 Others
1.3 Eosinophilic Granulomatosis Segment by Application
1.3.1 Global Eosinophilic Granulomatosis Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Others
1.4 Global Eosinophilic Granulomatosis Market Size Estimates and Forecasts
1.4.1 Global Eosinophilic Granulomatosis Revenue 2019-2030
1.4.2 Global Eosinophilic Granulomatosis Sales 2019-2030
1.4.3 Global Eosinophilic Granulomatosis Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Eosinophilic Granulomatosis Market Competition by Manufacturers
2.1 Global Eosinophilic Granulomatosis Sales Market Share by Manufacturers (2019-2024)
2.2 Global Eosinophilic Granulomatosis Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Eosinophilic Granulomatosis Average Price by Manufacturers (2019-2024)
2.4 Global Eosinophilic Granulomatosis Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Eosinophilic Granulomatosis, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Eosinophilic Granulomatosis, Product Type & Application
2.7 Eosinophilic Granulomatosis Market Competitive Situation and Trends
2.7.1 Eosinophilic Granulomatosis Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Eosinophilic Granulomatosis Players Market Share by Revenue
2.7.3 Global Eosinophilic Granulomatosis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Eosinophilic Granulomatosis Retrospective Market Scenario by Region
3.1 Global Eosinophilic Granulomatosis Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Eosinophilic Granulomatosis Global Eosinophilic Granulomatosis Sales by Region: 2019-2030
3.2.1 Global Eosinophilic Granulomatosis Sales by Region: 2019-2024
3.2.2 Global Eosinophilic Granulomatosis Sales by Region: 2025-2030
3.3 Global Eosinophilic Granulomatosis Global Eosinophilic Granulomatosis Revenue by Region: 2019-2030
3.3.1 Global Eosinophilic Granulomatosis Revenue by Region: 2019-2024
3.3.2 Global Eosinophilic Granulomatosis Revenue by Region: 2025-2030
3.4 North America Eosinophilic Granulomatosis Market Facts & Figures by Country
3.4.1 North America Eosinophilic Granulomatosis Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Eosinophilic Granulomatosis Sales by Country (2019-2030)
3.4.3 North America Eosinophilic Granulomatosis Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Eosinophilic Granulomatosis Market Facts & Figures by Country
3.5.1 Europe Eosinophilic Granulomatosis Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Eosinophilic Granulomatosis Sales by Country (2019-2030)
3.5.3 Europe Eosinophilic Granulomatosis Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Eosinophilic Granulomatosis Market Facts & Figures by Country
3.6.1 Asia Pacific Eosinophilic Granulomatosis Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Eosinophilic Granulomatosis Sales by Country (2019-2030)
3.6.3 Asia Pacific Eosinophilic Granulomatosis Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Eosinophilic Granulomatosis Market Facts & Figures by Country
3.7.1 Latin America Eosinophilic Granulomatosis Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Eosinophilic Granulomatosis Sales by Country (2019-2030)
3.7.3 Latin America Eosinophilic Granulomatosis Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Eosinophilic Granulomatosis Market Facts & Figures by Country
3.8.1 Middle East and Africa Eosinophilic Granulomatosis Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Eosinophilic Granulomatosis Sales by Country (2019-2030)
3.8.3 Middle East and Africa Eosinophilic Granulomatosis Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Eosinophilic Granulomatosis Sales by Type (2019-2030)
4.1.1 Global Eosinophilic Granulomatosis Sales by Type (2019-2024)
4.1.2 Global Eosinophilic Granulomatosis Sales by Type (2025-2030)
4.1.3 Global Eosinophilic Granulomatosis Sales Market Share by Type (2019-2030)
4.2 Global Eosinophilic Granulomatosis Revenue by Type (2019-2030)
4.2.1 Global Eosinophilic Granulomatosis Revenue by Type (2019-2024)
4.2.2 Global Eosinophilic Granulomatosis Revenue by Type (2025-2030)
4.2.3 Global Eosinophilic Granulomatosis Revenue Market Share by Type (2019-2030)
4.3 Global Eosinophilic Granulomatosis Price by Type (2019-2030)
5 Segment by Application
5.1 Global Eosinophilic Granulomatosis Sales by Application (2019-2030)
5.1.1 Global Eosinophilic Granulomatosis Sales by Application (2019-2024)
5.1.2 Global Eosinophilic Granulomatosis Sales by Application (2025-2030)
5.1.3 Global Eosinophilic Granulomatosis Sales Market Share by Application (2019-2030)
5.2 Global Eosinophilic Granulomatosis Revenue by Application (2019-2030)
5.2.1 Global Eosinophilic Granulomatosis Revenue by Application (2019-2024)
5.2.2 Global Eosinophilic Granulomatosis Revenue by Application (2025-2030)
5.2.3 Global Eosinophilic Granulomatosis Revenue Market Share by Application (2019-2030)
5.3 Global Eosinophilic Granulomatosis Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GlaxoSmithKline Eosinophilic Granulomatosis Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Pharmaceuticals Holdings
6.2.1 Pharmaceuticals Holdings Corporation Information
6.2.2 Pharmaceuticals Holdings Description and Business Overview
6.2.3 Pharmaceuticals Holdings Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pharmaceuticals Holdings Eosinophilic Granulomatosis Product Portfolio
6.2.5 Pharmaceuticals Holdings Recent Developments/Updates
6.3 Baxter
6.3.1 Baxter Corporation Information
6.3.2 Baxter Description and Business Overview
6.3.3 Baxter Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Baxter Eosinophilic Granulomatosis Product Portfolio
6.3.5 Baxter Recent Developments/Updates
6.4 Genentech(Roche)
6.4.1 Genentech(Roche) Corporation Information
6.4.2 Genentech(Roche) Description and Business Overview
6.4.3 Genentech(Roche) Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Genentech(Roche) Eosinophilic Granulomatosis Product Portfolio
6.4.5 Genentech(Roche) Recent Developments/Updates
6.5 Cephalon(Teva)
6.5.1 Cephalon(Teva) Corporation Information
6.5.2 Cephalon(Teva) Description and Business Overview
6.5.3 Cephalon(Teva) Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Cephalon(Teva) Eosinophilic Granulomatosis Product Portfolio
6.5.5 Cephalon(Teva) Recent Developments/Updates
6.6 Amgen
6.6.1 Amgen Corporation Information
6.6.2 Amgen Description and Business Overview
6.6.3 Amgen Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Amgen Eosinophilic Granulomatosis Product Portfolio
6.6.5 Amgen Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Eosinophilic Granulomatosis Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 DSM
6.8.1 DSM Corporation Information
6.8.2 DSM Description and Business Overview
6.8.3 DSM Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.8.4 DSM Eosinophilic Granulomatosis Product Portfolio
6.8.5 DSM Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Corporation Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.9.4 AstraZeneca Eosinophilic Granulomatosis Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Novartis International
6.10.1 Novartis International Corporation Information
6.10.2 Novartis International Description and Business Overview
6.10.3 Novartis International Eosinophilic Granulomatosis Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Novartis International Eosinophilic Granulomatosis Product Portfolio
6.10.5 Novartis International Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Eosinophilic Granulomatosis Industry Chain Analysis
7.2 Eosinophilic Granulomatosis Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Eosinophilic Granulomatosis Production Mode & Process
7.4 Eosinophilic Granulomatosis Sales and Marketing
7.4.1 Eosinophilic Granulomatosis Sales Channels
7.4.2 Eosinophilic Granulomatosis Distributors
7.5 Eosinophilic Granulomatosis Customers
8 Eosinophilic Granulomatosis Market Dynamics
8.1 Eosinophilic Granulomatosis Industry Trends
8.2 Eosinophilic Granulomatosis Market Drivers
8.3 Eosinophilic Granulomatosis Market Challenges
8.4 Eosinophilic Granulomatosis Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Eosinophilic Granulomatosis Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Eosinophilic Granulomatosis Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Eosinophilic Granulomatosis Market Competitive Situation by Manufacturers in 2023
Table 4. Global Eosinophilic Granulomatosis Sales (Kiloton) of Key Manufacturers (2019-2024)
Table 5. Global Eosinophilic Granulomatosis Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Eosinophilic Granulomatosis Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Eosinophilic Granulomatosis Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Eosinophilic Granulomatosis Average Price (US$/Ton) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Eosinophilic Granulomatosis, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Eosinophilic Granulomatosis, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Eosinophilic Granulomatosis, Product Type & Application
Table 12. Global Key Manufacturers of Eosinophilic Granulomatosis, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Eosinophilic Granulomatosis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eosinophilic Granulomatosis as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Eosinophilic Granulomatosis Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Eosinophilic Granulomatosis Sales by Region (2019-2024) & (Kiloton)
Table 18. Global Eosinophilic Granulomatosis Sales Market Share by Region (2019-2024)
Table 19. Global Eosinophilic Granulomatosis Sales by Region (2025-2030) & (Kiloton)
Table 20. Global Eosinophilic Granulomatosis Sales Market Share by Region (2025-2030)
Table 21. Global Eosinophilic Granulomatosis Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Eosinophilic Granulomatosis Revenue Market Share by Region (2019-2024)
Table 23. Global Eosinophilic Granulomatosis Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Eosinophilic Granulomatosis Revenue Market Share by Region (2025-2030)
Table 25. North America Eosinophilic Granulomatosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Eosinophilic Granulomatosis Sales by Country (2019-2024) & (Kiloton)
Table 27. North America Eosinophilic Granulomatosis Sales by Country (2025-2030) & (Kiloton)
Table 28. North America Eosinophilic Granulomatosis Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Eosinophilic Granulomatosis Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Eosinophilic Granulomatosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Eosinophilic Granulomatosis Sales by Country (2019-2024) & (Kiloton)
Table 32. Europe Eosinophilic Granulomatosis Sales by Country (2025-2030) & (Kiloton)
Table 33. Europe Eosinophilic Granulomatosis Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Eosinophilic Granulomatosis Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Eosinophilic Granulomatosis Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Eosinophilic Granulomatosis Sales by Region (2019-2024) & (Kiloton)
Table 37. Asia Pacific Eosinophilic Granulomatosis Sales by Region (2025-2030) & (Kiloton)
Table 38. Asia Pacific Eosinophilic Granulomatosis Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Eosinophilic Granulomatosis Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Eosinophilic Granulomatosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Eosinophilic Granulomatosis Sales by Country (2019-2024) & (Kiloton)
Table 42. Latin America Eosinophilic Granulomatosis Sales by Country (2025-2030) & (Kiloton)
Table 43. Latin America Eosinophilic Granulomatosis Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Eosinophilic Granulomatosis Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Eosinophilic Granulomatosis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Eosinophilic Granulomatosis Sales by Country (2019-2024) & (Kiloton)
Table 47. Middle East & Africa Eosinophilic Granulomatosis Sales by Country (2025-2030) & (Kiloton)
Table 48. Middle East & Africa Eosinophilic Granulomatosis Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Eosinophilic Granulomatosis Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Eosinophilic Granulomatosis Sales (Kiloton) by Type (2019-2024)
Table 51. Global Eosinophilic Granulomatosis Sales (Kiloton) by Type (2025-2030)
Table 52. Global Eosinophilic Granulomatosis Sales Market Share by Type (2019-2024)
Table 53. Global Eosinophilic Granulomatosis Sales Market Share by Type (2025-2030)
Table 54. Global Eosinophilic Granulomatosis Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Eosinophilic Granulomatosis Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Eosinophilic Granulomatosis Revenue Market Share by Type (2019-2024)
Table 57. Global Eosinophilic Granulomatosis Revenue Market Share by Type (2025-2030)
Table 58. Global Eosinophilic Granulomatosis Price (US$/Ton) by Type (2019-2024)
Table 59. Global Eosinophilic Granulomatosis Price (US$/Ton) by Type (2025-2030)
Table 60. Global Eosinophilic Granulomatosis Sales (Kiloton) by Application (2019-2024)
Table 61. Global Eosinophilic Granulomatosis Sales (Kiloton) by Application (2025-2030)
Table 62. Global Eosinophilic Granulomatosis Sales Market Share by Application (2019-2024)
Table 63. Global Eosinophilic Granulomatosis Sales Market Share by Application (2025-2030)
Table 64. Global Eosinophilic Granulomatosis Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Eosinophilic Granulomatosis Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Eosinophilic Granulomatosis Revenue Market Share by Application (2019-2024)
Table 67. Global Eosinophilic Granulomatosis Revenue Market Share by Application (2025-2030)
Table 68. Global Eosinophilic Granulomatosis Price (US$/Ton) by Application (2019-2024)
Table 69. Global Eosinophilic Granulomatosis Price (US$/Ton) by Application (2025-2030)
Table 70. GlaxoSmithKline Corporation Information
Table 71. GlaxoSmithKline Description and Business Overview
Table 72. GlaxoSmithKline Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 73. GlaxoSmithKline Eosinophilic Granulomatosis Product
Table 74. GlaxoSmithKline Recent Developments/Updates
Table 75. Pharmaceuticals Holdings Corporation Information
Table 76. Pharmaceuticals Holdings Description and Business Overview
Table 77. Pharmaceuticals Holdings Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 78. Pharmaceuticals Holdings Eosinophilic Granulomatosis Product
Table 79. Pharmaceuticals Holdings Recent Developments/Updates
Table 80. Baxter Corporation Information
Table 81. Baxter Description and Business Overview
Table 82. Baxter Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 83. Baxter Eosinophilic Granulomatosis Product
Table 84. Baxter Recent Developments/Updates
Table 85. Genentech(Roche) Corporation Information
Table 86. Genentech(Roche) Description and Business Overview
Table 87. Genentech(Roche) Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 88. Genentech(Roche) Eosinophilic Granulomatosis Product
Table 89. Genentech(Roche) Recent Developments/Updates
Table 90. Cephalon(Teva) Corporation Information
Table 91. Cephalon(Teva) Description and Business Overview
Table 92. Cephalon(Teva) Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 93. Cephalon(Teva) Eosinophilic Granulomatosis Product
Table 94. Cephalon(Teva) Recent Developments/Updates
Table 95. Amgen Corporation Information
Table 96. Amgen Description and Business Overview
Table 97. Amgen Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 98. Amgen Eosinophilic Granulomatosis Product
Table 99. Amgen Recent Developments/Updates
Table 100. Sanofi Corporation Information
Table 101. Sanofi Description and Business Overview
Table 102. Sanofi Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 103. Sanofi Eosinophilic Granulomatosis Product
Table 104. Sanofi Recent Developments/Updates
Table 105. DSM Corporation Information
Table 106. DSM Description and Business Overview
Table 107. DSM Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 108. DSM Eosinophilic Granulomatosis Product
Table 109. DSM Recent Developments/Updates
Table 110. AstraZeneca Corporation Information
Table 111. AstraZeneca Description and Business Overview
Table 112. AstraZeneca Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 113. AstraZeneca Eosinophilic Granulomatosis Product
Table 114. AstraZeneca Recent Developments/Updates
Table 115. Novartis International Corporation Information
Table 116. Novartis International Description and Business Overview
Table 117. Novartis International Eosinophilic Granulomatosis Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 118. Novartis International Eosinophilic Granulomatosis Product
Table 119. Novartis International Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Eosinophilic Granulomatosis Distributors List
Table 123. Eosinophilic Granulomatosis Customers List
Table 124. Eosinophilic Granulomatosis Market Trends
Table 125. Eosinophilic Granulomatosis Market Drivers
Table 126. Eosinophilic Granulomatosis Market Challenges
Table 127. Eosinophilic Granulomatosis Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Eosinophilic Granulomatosis
Figure 2. Global Eosinophilic Granulomatosis Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Eosinophilic Granulomatosis Market Share by Type in 2023 & 2030
Figure 4. Oral Product Picture
Figure 5. Intravenous Product Picture
Figure 6. Others Product Picture
Figure 7. Global Eosinophilic Granulomatosis Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Eosinophilic Granulomatosis Market Share by Application in 2023 & 2030
Figure 9. Hospital Pharmacies
Figure 10. Drug Stores
Figure 11. Others
Figure 12. Global Eosinophilic Granulomatosis Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Eosinophilic Granulomatosis Market Size (2019-2030) & (US$ Million)
Figure 14. Global Eosinophilic Granulomatosis Sales (2019-2030) & (Kiloton)
Figure 15. Global Eosinophilic Granulomatosis Average Price (US$/Ton) & (2019-2030)
Figure 16. Eosinophilic Granulomatosis Report Years Considered
Figure 17. Eosinophilic Granulomatosis Sales Share by Manufacturers in 2023
Figure 18. Global Eosinophilic Granulomatosis Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Eosinophilic Granulomatosis Players: Market Share by Revenue in 2023
Figure 20. Eosinophilic Granulomatosis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Eosinophilic Granulomatosis Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Eosinophilic Granulomatosis Sales Market Share by Country (2019-2030)
Figure 23. North America Eosinophilic Granulomatosis Revenue Market Share by Country (2019-2030)
Figure 24. United States Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Eosinophilic Granulomatosis Sales Market Share by Country (2019-2030)
Figure 27. Europe Eosinophilic Granulomatosis Revenue Market Share by Country (2019-2030)
Figure 28. Germany Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Eosinophilic Granulomatosis Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Eosinophilic Granulomatosis Revenue Market Share by Region (2019-2030)
Figure 35. China Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Eosinophilic Granulomatosis Sales Market Share by Country (2019-2030)
Figure 45. Latin America Eosinophilic Granulomatosis Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Eosinophilic Granulomatosis Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Eosinophilic Granulomatosis Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Eosinophilic Granulomatosis Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Eosinophilic Granulomatosis by Type (2019-2030)
Figure 55. Global Revenue Market Share of Eosinophilic Granulomatosis by Type (2019-2030)
Figure 56. Global Eosinophilic Granulomatosis Price (US$/Ton) by Type (2019-2030)
Figure 57. Global Sales Market Share of Eosinophilic Granulomatosis by Application (2019-2030)
Figure 58. Global Revenue Market Share of Eosinophilic Granulomatosis by Application (2019-2030)
Figure 59. Global Eosinophilic Granulomatosis Price (US$/Ton) by Application (2019-2030)
Figure 60. Eosinophilic Granulomatosis Value Chain
Figure 61. Eosinophilic Granulomatosis Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
